Melanoma-associated antigen
From Proteopedia
(Difference between revisions)
| (10 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | <StructureSection load='7uoa' size='340' side='right' caption=' | + | <StructureSection load='7uoa' size='340' side='right' caption='Human MAGEA4 MAGE homology domain (grey) complex with peptide inhibitor (green), ethanediol, ethylene glycol and TRIS (PDB id [[7uoa]])' scene='10/1042609/Cv/1'> |
== Function == | == Function == | ||
| - | '''Melanoma-associated antigen''' (MAGE) are produced by tumor cells and are recognized by cytotoxic T lymphocytes<ref>PMID:9740504</ref>. Many such antigens have been identified and are classified into 2 groups with group I called cancer/testis antigens<ref>PMID:15222021</ref>. | + | '''Melanoma-associated antigen''' (MAGE) are produced by tumor cells and are recognized by cytotoxic T lymphocytes<ref>PMID:9740504</ref>. Many such antigens have been identified and are classified into 2 groups with group I called cancer/testis antigens<ref>PMID:15222021</ref>. The loss of MAGE expression is observed in primary melanoma<ref>PMID:14676635</ref>. |
== Disease == | == Disease == | ||
== Relevance == | == Relevance == | ||
| + | |||
| + | The expression of MAGE-A1 can be a marker for the prediction of resistance to taxan-based chemotherapy in pations with gastric cancer<ref>PMID:17611652</ref>. Assessment of MAGE may provide stratification factor for active-specific immunotherapy<ref>PMID:12543800</ref>. | ||
== Structural highlights == | == Structural highlights == | ||
| - | + | The 3D structure of the complex between MAGE-A4 and the peptide inhibitor shows the peptide to bind in a cyclic conformation. The <scene name='10/1042609/Cv/3'>peptide is anchored by 3 of its residues</scene> interacting with MAGE hydrophobic pocket. MAGE residue <scene name='10/1042609/Cv/5'>M161 makes Met-aromatic interactions with 2 of the peptide Tyr residues</scene>. Additional <scene name='10/1042609/Cv/6'>H-bonds</scene> are formed between the peptide inhibitor and MAGE<ref>PMID:35522528</ref>. | |
==3D structures of melanoma-associated antigen== | ==3D structures of melanoma-associated antigen== | ||
Current revision
| |||||||||||
References
- ↑ Kirkin AF, Dzhandzhugazyan K, Zeuthen J. Melanoma-associated antigens recognized by cytotoxic T lymphocytes. APMIS. 1998 Jul;106(7):665-79. PMID:9740504 doi:10.1111/j.1699-0463.1998.tb00210.x
- ↑ Xiao J, Chen HS. Biological functions of melanoma-associated antigens. World J Gastroenterol. 2004 Jul 1;10(13):1849-53. PMID:15222021 doi:10.3748/wjg.v10.i13.1849
- ↑ Hofbauer GF, Burkhart A, Schüler G, Dummer R, Burg G, Nestle FO. High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma. J Immunother. 2004 Jan-Feb;27(1):73-8. PMID:14676635 doi:10.1097/00002371-200401000-00007
- ↑ Suzuki T, Yoshida K, Wada Y, Hamai Y, Sentani K, Oue N, Yasui W. Melanoma-associated antigen-A1 expression predicts resistance to docetaxel and paclitaxel in advanced and recurrent gastric cancer. Oncol Rep. 2007 Aug;18(2):329-36 PMID:17611652
- ↑ Takeuchi H, Kuo C, Morton DL, Wang HJ, Hoon DS. Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res. 2003 Jan 15;63(2):441-8 PMID:12543800
- ↑ Fleming MC, Chiou LF, Tumbale PP, Droby GN, Lim J, Norris-Drouin JL, Williams JG, Pearce KH, Williams RS, Vaziri C, Bowers AA. Discovery and Structural Basis of the Selectivity of Potent Cyclic Peptide Inhibitors of MAGE-A4. J Med Chem. 2022 May 26;65(10):7231-7245. doi: 10.1021/acs.jmedchem.2c00185. Epub, 2022 May 6. PMID:35522528 doi:http://dx.doi.org/10.1021/acs.jmedchem.2c00185
